

## Cipla Limited - Company Snapshot & SWOT Analysis

https://marketpublishers.com/r/C5D7D7173F1EN.html Date: June 2019 Pages: 20 Price: US\$ 200.00 (Single User License) ID: C5D7D7173F1EN

### Abstracts

Chemical, Industrial & Pharmaceutical Laboratories, now known as Cipla, was incorporated in 1935. Cipla Limited was founded by Dr. K.A. Hamied. Cipla is a therapy leader in India for anti-malarial with a market share of over 34%. CIPLA has 34 manufacturing facilities.

The Revenues of CIPLA increased from INR 104.39 bn to INR 155.77 bn during 2014-2018. The growth rate of the company for 2014-2018 is around 10.52%.

In the next five years, the company is estimated to grow at a CAGR of 7.50%. The revenue is expected to reach INR 223.63 billion by 2023.

Scope of the Cipla Limited - Company Snapshot & SWOT Analysis Report

This report provides detailed information about Cipla Limited including value chain analysis, financial performance, business strategy and SWOT analysis.

The report identifies the growth drivers and inhibitors for global pharmaceutical market.

This report provides information about current and future trends for global pharmaceutical market.



## Contents

#### **1. EXECUTIVE SUMMARY**

Scope of the Cipla Limited - Company Snapshot & SWOT Analysis Report Research Methodology

#### 2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET

#### **3. COMPANY PROFILE**

- 3.1 CIPLA Limited
  - 3.1.1 Company Profile
  - 3.1.2 CIPLA Limited in Pharmaceutical Manufacturing Value Chain
  - 3.1.3 CIPLA Limited: Financial Performance
  - 3.1.4 CIPLA Limited: Business Strategy
  - 3.1.4.1 Product Level Business Strategy
  - 3.1.4.2 Service Level Business Strategy
  - 3.1.5 SWOT Analysis of CIPLA Limited
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats
  - 3.1.6 Key Customers of CIPLA Limited

#### 4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET

Orphan Drugs Biologics and Biosimilars Current Trends

#### **1. INCREASING SEVERITY OF DRUG PRICE CONTROLS**

#### 2. GREATER FOCUS ON RARE DISEASES / ORPHAN DRUGS

#### 3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS

#### 4. INCREASING FOCUS ON CELL THERAPY



#### 5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM

#### 6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS

# 7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY

Notes Company Information



## **List Of Exhibits**

#### LIST OF EXHIBITS

Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market Exhibit 3.1 Key Information of Cipla Limited Exhibit 3.2 Contact Information of Cipla Limited Exhibit 3.3 Cipla Limited in Pharmaceutical Manufacturing Value Chain Exhibit 3.4 Cipla Limited Revenue 2014-2018 (in INR billion) Exhibit 3.5 Year-wise Cipla Limited Revenue Growth 2014-2018 (in %) Exhibit 3.6 Estimated Cipla Ltd. Revenue (in INR bn) Exhibit 3.7 Key Products of Cipla Limited Exhibit 3.8 Key Services of Cipla Limited Exhibit 3.9 SWOT Analysis of Cipla Limited



#### I would like to order

Product name: Cipla Limited - Company Snapshot & SWOT Analysis Product link: <u>https://marketpublishers.com/r/C5D7D7173F1EN.html</u> Price: US\$ 200.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

#### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/C5D7D7173F1EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970